Valuation: SCYNEXIS, Inc.

Market Cap 3.84Cr 3.36Cr 3.11Cr 2.9Cr 5.46Cr 363.34Cr 5.59Cr 37Cr 14Cr 179.25Cr 14Cr 14Cr 622.33Cr P/E 2026 *
-0.95x
P/E 2027 * -1.54x
Enterprise Value 3.84Cr 3.36Cr 3.11Cr 2.9Cr 5.46Cr 363.34Cr 5.59Cr 37Cr 14Cr 179.25Cr 14Cr 14Cr 622.33Cr EV / Sales 2026 *
33.3x
EV / Sales 2027 * 5.76x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day+2.33%
1 week+3.93%
Current month-29.61%
1 month-25.52%
3 months-37.16%
6 months-18.06%
Current year-21.53%
1 week 3.7
Extreme 3.695
3.97
1 month 3.68
Extreme 3.68
5.62
Current year 3.68
Extreme 3.68
9.12
1 year 3.68
Extreme 3.68
10.48
3 years 3.68
Extreme 3.68
30.96
5 years 3.68
Extreme 3.68
64.8
10 years 3.68
Extreme 3.68
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 65 24/10/2022
Chief Tech/Sci/R&D Officer - 01/10/2020
Director TitleAgeSince
Director/Board Member 68 21/01/2019
Director/Board Member 64 24/09/2015
Director/Board Member 73 01/12/2008
Date Insider Type Main position Quantity % Market Cap.
01/04Buy

Chief Executive Officer

2,17,390 0.2736%
29/01Free

General Counsel

1,29,833 0.3094%
29/01Free

Chief Financial Officer

1,29,833 0.3094%
Change 5-day change 1-year change 3-year change Capi.($)
+2.33%+3.93%-26.46%-83.18% 3.84Cr
-1.03%+11.00%+57.65%+162.04% 1,09700Cr
-0.58%+8.51%+69.83%+56.73% 62TCr
-0.51%+8.70%+37.48%+89.41% 45TCr
-1.17%+6.34%+29.51%+24.01% 33TCr
-0.15%+5.84%+42.13%+27.56% 29TCr
+0.75%+3.47%+32.79%+41.89% 29TCr
+0.50%+3.44%-27.58%-42.09% 21TCr
-0.03%+4.32%+29.66%+63.05% 19TCr
-0.67%+0.97%+13.89%+63.83% 16TCr
Average +0.02%+5.61%+25.89%+40.33% 36.47TCr
Weighted average by Cap. -0.49%+8.72%+43.11%+80.78%

Financials

2026 *2027 *
Net sales 11.54L 10.1L 9L 9L 16.4L 11Cr 16.77L 1.12Cr 43.34L 5.38Cr 43.34L 42.39L 19Cr 66.77L 58.47L 53.97L 50.4L 94.88L 63Cr 97.04L 6.5Cr 2.51Cr 31Cr 2.51Cr 2.45Cr 108.13Cr
Net income -4.11Cr -3.6Cr -3.32Cr -3.1Cr -5.84Cr -388.33Cr -5.97Cr -40Cr -15Cr -191.58Cr -15Cr -15Cr -665.13Cr -2.87Cr -2.52Cr -2.32Cr -2.17Cr -4.08Cr -271.62Cr -4.18Cr -28Cr -11Cr -134Cr -11Cr -11Cr -465.23Cr
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
30/26/30 $3.970 +2.58% 1,041
29/26/29 $3.870 +0.52% 32,140
26/26/26 $3.850 +1.05% 49,109
25/26/25 $3.810 -1.55% 47,373
24/26/24 $3.870 +1.31% 28,667
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.870USD
Average target price
33.55USD
Spread / Average Target
+766.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock